Literature DB >> 28169486

Hepatic vena cava syndrome: New concept of pathogenesis.

Santosh Man Shrestha1, Masayoshi Kage2, Byung Boong Lee3.   

Abstract

Hepatic vena cava syndrome, also known as membranous obstruction of inferior vena cava (IVC), was considered a rare congenital disease and classified under Budd-Chiari syndrome. It is now recognized as a bacterial infection-induced disease related to poor hygiene. Localized thrombophlebitis of the IVC at the site close to hepatic vein outlets is the initial lesion which converts on resolution into stenosis or complete obstruction, the circulatory equilibrium being maintained by development of cavo-caval collateral anastomosis. These changes persist for the rest of the patient's life. The patient remains asymptomatic for a variable period until acute exacerbations occur, precipitated by bacterial infection, resulting in deposition of thrombi at the site of the lesion and endophlebitis in intrahepatic veins. Large thrombus close to hepatic vein outlets results in ascites from hepatic venous outflow obstruction, which is followed by development of venocentric cirrhosis. Endophlebitis of intrahepatic veins results in ischemic liver damage and development of segmental stenosis or membrane. Acute exacerbations are recognized clinically as intermittent jaundice and/or elevation of aminotransferase or ascites associated with neutrophil leukocytosis and elevation of C-reactive protein; sonologically, they are recognized as the presence of thrombi of different ages in IVC and thrombosis of intrahepatic veins. Development of liver cirrhosis and hepatocellular carcinoma is related to severity or frequency of acute exacerbations and not to duration or type of caval obstruction. Hepatic vena cava syndrome is a common co-morbid condition with other liver diseases in developing countries and it should be considered in differential diagnosis in patient with intermittent elevation serum bilirubin and or aminotransferase or development of ascites and cirrhosis.
© 2017 The Japan Society of Hepatology.

Entities:  

Keywords:  Budd-Chiari syndrome; ascites; bacterial peritonitis; hepatic venous outflow obstruction; hepatocellular carcinoma; liver cirrhosis

Year:  2017        PMID: 28169486     DOI: 10.1111/hepr.12869

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  5 in total

1.  Splenomegaly and hypersplenism in hepatic vena cava syndrome.

Authors:  Santosh Man Shrestha
Journal:  Hepatol Forum       Date:  2021-05-24

2.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

3.  Trapped vessel of abdominal pain with hepatomegaly: A case report.

Authors:  Sirisha Grandhe; Joy A Lee; Ankur Chandra; Christopher Marsh; Catherine T Frenette
Journal:  World J Hepatol       Date:  2018-11-27

Review 4.  State of the Art, Current Perspectives, and Controversies of Budd-Chiari Syndrome: A Review.

Authors:  Paschalis Gavriilidis; Gabriele Marangoni; Jawad Ahmad; Daniel Azoulay
Journal:  J Clin Med Res       Date:  2022-04-30

5.  Budd-Chiari Syndrome during Long-term Follow-up after Allogeneic Umbilical Cord Blood Transplantation.

Authors:  Yusuke Akitomi; Yoshinari Asaoka; Ryo Miura; Sae Murata; Takatsugu Yamamoto; Haruko Tashiro; Naoki Shirafuji; Kentaro Yamada; Masayoshi Yamamoto; Hiroshi Kondo; Atsushi Tanaka
Journal:  Intern Med       Date:  2021-10-26       Impact factor: 1.282

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.